Morepen transfers subsidiary shares to key management

morepen laboratories has transferred 1,62,000 equity shares of its subsidiary, Morepen Medipath Limited (MML), to Mr. Anubhav Suri, the Head of its Medical Devices Business. The decision follows 15 years of significant growth in the medical devices sector under his leadership. The company stated that the transfer is intended to align Mr. Suri's interests with the long-term growth and strategic objectives of MML, ensuring continuity of leadership as the business expands.

As a result of this transaction, Morepen Laboratories' shareholding in MML has decreased from 60% to 51%. Despite the reduction, MML will continue to remain a subsidiary of the company and will be consolidated in its financial statements. The consideration for the transfer was mutually agreed upon between the parties involved.

The shareholding pattern of MML has been revised following the transfer. Mr. Anubhav Suri, who previously held 0.10% equity shares, now holds 9.10% of the total paid-up share capital. The details of the pre and post-transaction shareholding are outlined below.

Shareholder Category Pre-Transaction Shares Pre-Transaction % Post-Transaction Shares Post-Transaction % Morepen Laboratories Limited Promoter 10,80,000 60.00% 9,18,000 51.00% Entity/ Persons belonging to promoters & promoter group of MLL Promoter Group 6,08,200 33.79% 6,08,200 33.79% Mr. Anubhav Suri Promoter Group 1,800 0.10% 1,63,800 9.10% Others Public 1,10,000 6.11% 1,10,000 6.11% Total 18,00,000 100% 18,00,000 100%

The disclosure was made in terms of Regulation 30 read with a SEBI master circular. The company's Corporate Office is located in Gurugram, Haryana, and its Registered Office is in Baddi, Himachal Pradesh.

Morepen Laboratories Limited has informed the stock exchanges of a scheduled Board of Directors meeting on Friday, May 22, 2026, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The meeting has been convened, inter-alia, to consider and approve the audited standalone and consolidated financial results of the company for the quarter and financial year ended March 31, 2026.

Board Meeting Details

The intimation, dated May 15, 2026, was addressed to both the National Stock Exchange of India Ltd. and BSE Limited. The key details of the scheduled board meeting are outlined below:

Parameter: Details Meeting Date: Friday, May 22, 2026 Purpose: Approval of audited standalone and consolidated financial results Period Under Review: Quarter and financial year ended March 31, 2026 Regulatory Reference: Regulation 29, SEBI (LODR) Regulations, 2015 Intimation Date: May 15, 2026

Trading Window Closure

In continuation of the company's earlier communication dated March 27, 2026, regarding the closure of the trading window under the company's Code of Conduct to Regulate, Monitor and Report of Trading by Insiders, Morepen Laboratories has confirmed that the trading window will continue to remain closed until 48 hours after the declaration of financial results.

The key details related to the trading window closure are as follows:

Trading window closure: Continues from the earlier intimation dated March 27, 2026

Applicable to: All designated persons and their immediate relatives of the company

Trading window reopens after: Sunday, May 24, 2026 (inclusive)

The intimation was signed by Vipul Kumar Srivastava, Company Secretary (F-12148), on behalf of Morepen Laboratories Limited.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.